Literature DB >> 12124340

The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers.

Yasuhiro Tada1, Morimasa Wada, Ken-Ichi Taguchi, Yasushi Mochida, Naoko Kinugawa, Masazumi Tsuneyoshi, Seiji Naito, Michihiko Kuwano.   

Abstract

Mechanisms for bladder carcinogenesis and the development of recurrentbladder cancer remain unclear. Aberrant methylation of the 5' CpG island is thought to play an important role in the inactivation of the tumor suppressor genes in cancer. To study whether specific or bulk hypermethylation predicts intrabladder recurrence, we determined the frequency of aberrant promoter hypermethylation of seven genes, hMLH1, O(6)-methylguanine-DNA-methyltransferase (MGMT), p16, Von Hippel-Lindau (VHL), death-associated protein kinase (DAP-kinase), glutathione S-transferase P1 (GST-P1) and E-cadherin in 55 superficial bladder cancers and 5 normal urothelial epithelia by methylation-specific PCR (MSP). These patients of superficial bladder cancer had been followed prospectively by cystoscopy. Simultaneous hypermethylation of three genes or more among the seven genes was observed in 2 (7%) of 30 patients in the nonrecurrence group and 7 (28%) of 25 patients in the recurrence group. There was a significant concordance between the number of methylated genes and the development of recurrence (P = 0.012). In particular, the recurrence rate for 24 months was 88% for hypermethylation of DAP-kinase and 28% for nonmethylation of DAP-kinase. Hypermethylation of DAP-kinase is, therefore, a strong indicator of the superficial bladder cancer associated with a high recurrence rate (P < 0.001; hazards ratio, 7.01). Our results suggest that hypermethylation of DAP-kinase might be a useful prognostic marker for disease recurrence in superficial bladder cancers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124340

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  DAPK promoter hypermethylation in tissues and body fluids of oral precancer patients.

Authors:  Yang Liu; Zeng-Tong Zhou; Qing-Bo He; Wei-Wen Jiang
Journal:  Med Oncol       Date:  2011-04-24       Impact factor: 3.064

Review 2.  Epigenetics of kidney cancer and bladder cancer.

Authors:  Amanda M Hoffman; Paul Cairns
Journal:  Epigenomics       Date:  2011-02       Impact factor: 4.778

3.  Hypermethylation in bladder cancer: biological pathways and translational applications.

Authors:  Marta Sánchez-Carbayo
Journal:  Tumour Biol       Date:  2012-01-25

4.  DNA hypermethylation profiles in squamous cell carcinoma of the vulva.

Authors:  Josena K Stephen; Kang Mei Chen; Misa Raitanen; Seija Grénman; Maria J Worsham
Journal:  Int J Gynecol Pathol       Date:  2009-01       Impact factor: 2.762

5.  Nucleophosmin1 associated with drug resistance and recurrence of bladder cancer.

Authors:  Huihui Hu; Qian Meng; Ting Lei; Man Zhang
Journal:  Clin Exp Med       Date:  2014-06-13       Impact factor: 3.984

6.  Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis.

Authors:  Carolyn D Hurst; Fiona M Platt; Claire F Taylor; Margaret A Knowles
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

Review 7.  Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis.

Authors:  Zdenko Herceg; Pierre Hainaut
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

8.  Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study.

Authors:  Sonata Jarmalaite; Rasa Andrekute; Asta Scesnaite; Kestutis Suziedelis; Kirsti Husgafvel-Pursiainen; Feliksas Jankevicius
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-19       Impact factor: 4.553

Review 9.  Epigenetics in bladder cancer.

Authors:  Hideki Enokida; Masayuki Nakagawa
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

10.  Prognostic Value of Promoter Hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (p16/MTS1) in Prostate Cancer.

Authors:  Ahmad Ameri; Asdollah Alidoosti; Seyed Yousef Hosseini; Mohammad Parvin; Mohammad Hasan Emranpour; Farnaz Taslimi; Eisa Salehi; Pedram Fadavip
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.